Search results
Results from the WOW.Com Content Network
Tin(II) sulfate (Sn S O 4) is a chemical compound. It is a white solid that can absorb enough moisture from the air to become fully dissolved, forming an aqueous solution; this property is known as deliquescence. It can be prepared by a displacement reaction between metallic tin and copper(II) sulfate: [3] Sn (s) + CuSO 4 (aq) → Cu (s) + SnSO ...
Infection rates dropped and stabilised throughout 2022 and 2023, leading to the end of COVID-19's classification as a severe transmissible disease in June 2023. [22] Although the pandemic has heavily disrupted the country's economy, [23] Vietnam's GDP growth rate has remained one of the highest in Asia-Pacific, at 2.91% in 2020. Due to the more ...
Coronavirus disease 2019 (COVID-19, also known as SARS-2) is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic. The symptoms of COVID‑19 can vary but often include fever, [7] fatigue, cough, breathing difficulties, loss of smell, and loss of taste.
The phase III study is the adaptive, multicenter, randomized, double-blind, placebo control study to evaluate the safety, immunogenicity, and efficacy of the Nanocovax vaccine against COVID-19 in volunteer subjects 18 years of age and older. [17]
A police car in Hanoi with COVID-19 public health messaging. The Vietnamese government using social media platforms to keep the public informed of COVID-19 news and instructions. Thong Tin Chinh Phu (Governmental Information), the government's official Facebook page, provides nearly hourly updates on the country's pandemic situation. Zalo, a ...
ARCT-154, also known as VBC-COV19-154 in Vietnam, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics. [ 2 ] [ 3 ] For its development, Arcturus collaborated with Vinbiocare , a Vietnamese company, for support with clinical trials and manufacturing.
NDV-HXP-S (known as ButanVac [2] [3] or ADAPTCOV [4] in Brazil, COVIVAC [5] in Vietnam, HXP-GPOVac [6] in Thailand, Patria [7] in Mexico) is a COVID-19 vaccine candidate developed under the leadership of Peter Palese, Adolfo García-Sastre, and Florian Krammer at the Icahn School of Medicine at Mount Sinai.
[16] [17] [2] In results published in The Lancet, SCB-2019 resulted in a strong immune responses against COVID-19, with high viral neutralizing activity (antibody geometric mean titres were 1567–4452 with AS03 and 174–2440 with CpG/Alum). Both adjuvanted vaccines were well tolerated and determined to be suitable for further clinical ...